Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization (CRO) that specializes in preclinical drug discovery services, particularly in ion channel biology. Founded in September 2015, the company emerged from a management buyout of the research division of Xention Limited. Metrion is located at the Granta Centre in Cambridge and was established by directors Marc Rogers, John Ford, and Keith McCullagh, who aimed to utilize their extensive expertise in automated patch clamp electrophysiology. The company offers a wide range of drug discovery services, including ion channel screening and characterization, cardiac safety profiling, and neuronal screening services. Metrion also provides integrated drug discovery services that combine various scientific disciplines, as well as specialized assays for pain research. They engage with clients through both fee-for-service and collaboration models, delivering decision-ready data to support drug discovery programs. Metrion has built a strong reputation in the field, serving pharmaceutical and biotechnology clients globally.